Plus   Neg

Stock Alert: Genetic Technologies Surges 65%

Shares Genetic Technologies Ltd. (GENE) are currently surging over 65% after the molecular diagnostics company provided update on its COVID-19 PRS test.

GENE is currently trading at $7.15, up $2.85 or 66.28%, on the Nasdaq.

The company said total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients' data. Analysis confirms that the test is well calibrated.

Genetic Technologies anticipates submission for regulatory clearance via Centers for Medicare and Medicaid Services/Clinical Laboratory Improvement Amendments by the end of first quarter 2021 following final validation process of expanded dataset.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chico's FAS Inc. (CHS) Tuesday reported a wider year-over-year net loss for the fourth quarter. Meanwhile, Kohl's Corp.'s (KSS) fourth-quarter net income grew 29 percent from the previous year. But Abercrombie & Fitch Co.'s (ANF) fourth-quarter net income decreased 1 percent from the prior year. The U.S. Food and Drug Administration has approved the marketing of a new robotically-assisted surgical device (RASD) that can facilitate transvaginal hysterectomy in certain patients using minimally-invasive surgical instruments. The Hominis Surgical System of Memic Innovative Surgery Ltd., the U.S. subsidiary of Israeli biotechnology company memic Ltd., has been granted marketing authorization. Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com. Quatreau is a premium ready-to-drink...
Follow RTT